Your browser doesn't support javascript.
loading
Clinical and genetic analysis of a case of Gitelman syndrome accompanied with Graves disease and adrenocortical adenoma: A case report.
Qiao, Yan; Zhao, Jinghong; Wu, Ji; Cao, Lewei; Song, Guiqin; Mao, Jingxin.
Afiliação
  • Qiao Y; Department of Endocrinology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China.
  • Zhao J; Department of Endocrinology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China.
  • Wu J; Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China.
  • Cao L; Department of Endocrinology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China.
  • Song G; Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China.
  • Mao J; Chongqing Medical and Pharmaceutical College, Chongqing, China.
Medicine (Baltimore) ; 103(15): e37770, 2024 Apr 12.
Article em En | MEDLINE | ID: mdl-38608089
ABSTRACT
RATIONALE Gitelman syndrome (GS), also known as familial hypokalemia and hypomagnesemia, is a rare autosomal recessive inherited disease caused by primary renal desalinization caused by impaired reabsorption of sodium and chloride ions in the distal renal tubules. We report a case of clinical and genetic characteristics of GS accompanied with Graves disease and adrenocorticotrophic hormone (ACTH)-independent adrenocortical adenoma. PATIENT CONCERNS The patient is a 45 year old female, was admitted to our hospital, due to a left adrenal gland occupying lesion as the chief complaint. DIAGNOSIS The patient was finally diagnosed as GS with Graves disease and adrenocortical adenoma.

INTERVENTIONS:

Potassium magnesium aspartate (1788 mg/d, taken orally 3 times a day (supplement a few times a day, intake method, treatment duration). Contains 217.2 mg of potassium and 70.8 mg of magnesium, and potassium chloride (4.5 g/d, taken orally 3 times a day (supplement a few times a day, intake method, and treatment duration); Potassium 2356 mg), spironolactone (20 mg/d, taken orally once a day (supplement a few times a day, intake method, treatment duration). After 3 months of treatment, the patient's blood potassium fluctuated between 3.3-3.6 mmol/L, and blood magnesium fluctuated between 0.5-0.7 mmol/L, indicating a relief of fatigue symptoms.

OUTCOMES:

On the day 6 of hospitalization, the symptoms of dizziness, limb fatigue, fatigue and pain were completely relieved on patient. In the follow-up of the following year, no recurrence of the condition was found. LESSONS The novel c.1444-10(IVS11)G > A variation may be a splicing mutation. The compound heterozygous mutations of the SLC12A3 gene may be the pathogenic cause of this GS pedigree.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doença de Graves / Adenoma Adrenocortical / Síndrome de Gitelman Limite: Female / Humans / Middle aged Idioma: En Revista: Medicine (Baltimore) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doença de Graves / Adenoma Adrenocortical / Síndrome de Gitelman Limite: Female / Humans / Middle aged Idioma: En Revista: Medicine (Baltimore) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China